Breckenridge Pharmaceutical Secures FDA Approval for Methadone Injection

Breckenridge Pharmaceutical Achieves Milestone with FDA Approval

Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, has recently announced a significant advancement in its product line. The U.S. Food and Drug Administration (FDA) has granted final approval for the Methadone Hydrochloride Injection USP, specifically in the 200 mg/20 mL (10 mg/mL) multi-dose vial format. This pivotal approval opens the door for immediate product launch and availability for healthcare providers across the country.

Purpose and Application of Methadone Hydrochloride Injection

The Methadone Hydrochloride Injection is indicated for two primary medical uses: first, it is intended for managing severe and persistent pain requiring a prolonged period of treatment with opioid analgesics when other treatment alternatives fall short. Secondly, the injection serves as a temporary treatment for opioid dependence in patients unable to take oral medications. This dual-functionality positions the new product as a vital tool in the management of both pain and substance dependence.

Strategic Expansion into Institutional Channels

Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical, expressed the company's enthusiasm about this approval. He emphasized how expanding the product range into institutional channels will significantly enhance their capabilities to meet pressing healthcare needs across the board. This strategic move aligns with Breckenridge's dedication to innovation and growth, as the company aims to address the evolving demands of healthcare professionals while delivering superior patient care.

Alongside this approval, Breckenridge is set to diversify its pharmaceutical offerings by introducing a range of products aimed at treating conditions like Oncology, Autoimmune disorders, Rare Diseases, and other Supportive Care needs. This initiative reflects not only a response to market demands but also the company’s commitment to holistic health, resonating with the World Health Organization’s comprehensive definition of health, which encompasses physical, mental, and emotional dimensions.

Commitment to Quality and Patient Care

Breckenridge Pharmaceutical, which operates from its base in New Jersey, has a longstanding reputation for partnering with manufacturers both locally and internationally. Their mission is to supply high-quality, cost-efficient generic pharmaceuticals to patients throughout the United States. The company prides itself on exceptional customer service, timely delivery, and consistent supply, which are crucial aspects in the dynamic healthcare sector.

In summation, Breckenridge's approval from the FDA sets the stage for a more robust product lineup, poised to make a significant impact on patient treatment protocols and improve outcomes in pain management and opioid dependency. As they continue to push the boundaries of pharmaceutical innovation, Breckenridge Pharmaceutical remains committed to serving the unique needs of healthcare providers and patients alike in an ever-evolving landscape.

For further information, visit Breckenridge Pharmaceutical's official website at www.breckenridgepharma.com.